Valuation: PolyPid Ltd.

Market Cap 71.9M 63.1M 58.76M 54.05M 101M 6.87B 103M 697M 273M 3.41B 270M 264M 11.77B P/E 2026 *
-4.42x
P/E 2027 * -3.36x
Enterprise Value 71.9M 63.1M 58.76M 54.05M 101M 6.87B 103M 697M 273M 3.41B 270M 264M 11.77B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 8.38x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-5.78%
1 week+0.27%
Current month-26.18%
1 month-21.05%
3 months-15.35%
6 months-20.55%
Current year-13.59%
1 week 3.71
Extreme 3.713898
4.3
1 month 3.65
Extreme 3.65
5.73
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
12
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 30/06/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 17/08/2025
Director TitleAgeSince
Director/Board Member 84 31/03/2008
Director/Board Member 52 07/08/2022
Director/Board Member 74 30/11/2018
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Director

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-5.78%+0.27%+3.02%-63.25% 71.71M
+1.93%+3.85%+51.05%+166.24% 1,089B
+0.29%+6.43%+60.47%+52.87% 643B
+2.45%+2.77%+39.61%+74.48% 465B
-0.48%+10.23%+41.19%+35.40% 359B
-0.29%+3.73%+37.27%+42.77% 303B
+1.34%+3.08%+17.34%+17.05% 267B
-0.07%+4.77%-3.50%-38.70% 226B
+4.48%+7.33%+30.47%+66.31% 212B
+2.91%+3.10%+18.84%+74.76% 167B
Average +0.46%+4.59%+29.58%+42.79% 373.12B
Weighted average by Cap. +0.80%+5.14%+40.85%+79.76%

Financials

2026 *2027 *
Net sales 15M 13.16M 12.26M 11.27M 21.14M 1.43B 21.5M 145M 56.92M 711M 56.31M 55.1M 2.46B 8.58M 7.53M 7.01M 6.45M 12.09M 820M 12.3M 83.21M 32.57M 407M 32.22M 31.52M 1.4B
Net income -18.96M -16.64M -15.5M -14.25M -26.72M -1.81B -27.18M -184M -71.96M -898M -71.19M -69.65M -3.1B -27.7M -24.31M -22.64M -20.82M -39.03M -2.65B -39.7M -269M -105M -1.31B -104M -102M -4.53B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
28/07/26 US$3.750 -5.78% 139,612
27/07/26 US$3.980 +2.05% 91,139
24/07/26 US$3.900 -8.02% 286,505
23/07/26 US$4.240 +6.00% 302,140
22/07/26 US$4.000 +6.95% 439,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.750USD
Average target price
12.00USD
Spread / Average Target
+220.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock